May 2 |
Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide
|
May 2 |
Earnings Season: 3 Companies Boosting Guidance
|
May 2 |
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
|
May 2 |
Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript
|
May 2 |
GLP-1 drug prices falling at UK pharmacies, clinics: report
|
May 2 |
Novo sees Wegovy sales dip on lower price, tight supply
|
May 2 |
Eli Lilly and Company (NYSE:LLY) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
May 2 |
Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock’s Falling.
|
May 2 |
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
|
May 2 |
Here's Why Eli Lilly Stock Remains a Screaming Buy
|